In a report released yesterday, Jim Birchenough from Wells Fargo maintained a Hold rating on Intercept Pharma (ICPT). The company’s shares closed yesterday at $104.45.
According to TipRanks.com, Birchenough is a 5-star analyst with an average return of 22.0% and a 50.9% success rate. Birchenough covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Global Blood Therapeutics, and Bellicum Pharmaceuticals.
Intercept Pharma has an analyst consensus of Strong Buy, with a price target consensus of $164.88, implying a 57.9% upside from current levels. In a report issued on February 20, RBC Capital also maintained a Hold rating on the stock with a $137 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $133.74 and a one-year low of $58.03. Currently, Intercept Pharma has an average volume of 929.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
Read More on ICPT:
